By Dr Charles Edo de Bock

Preprints

Jing D; Beck D; Cao H; Tian F; Huang Y; Zhao H; Tai X; XU WENQIAN; Kosasih H; Kealy D; Bridge K; Zhao W; Holding A; Dowle A; Taylor S; Song G; Fajardo D; Walia Y; Wang M; Zhang C; Wang J; Mi J-Q; Lock R; de Bock C, 2024, PU.1 Eviction at Lymphocyte-Specific Chromatin Domains Mediates Glucocorticoid Response in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.21203/rs.3.rs-3872306/v1

Zhang Q; Li MK; Hu XY; Wang YY; Zhao PP; Cheng LN; Yu RH; Zhang XD; Chen S; Zhu ZM; de Bock C; Thorne R, 2023, The tumour suppressor Fat1 is dispensable for normal murine hematopoiesis, http://dx.doi.org/10.1101/2023.12.20.572284

Germon Z; Sillar J; Mannan A; Duchatel R; Staudt D; Murray H; Findlay I; Jackson E; McEwen H; Douglas A; McLachlan T; Schjenken J; Skerrett-Bryne D; Huang H; Melo-Braga M; Plank M; Alvaro F; Chamberlain J; Iuliis GD; Aitken J; Nixon B; Wei A; Enjeti A; Lock R; Larsen M; Lee H; de Bock C; Verrills N; Dun M, 2022, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Back to profile page